Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Trial Identifier: 205801-003
Sponsor: GlaxoSmithKline
Start Date: December 2021
Primary Completion Date: May 2024
Study Completion Date: May 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
gsk-205801-003-layperson-summary of-results-Sub-study-003
gsk-205801-003-layperson-summary of-results-frfr-Sub-study-003
gsk-205801-003-layperson-summary of-results-itit-Sub-study-003
gsk-205801-003-layperson-summary of-results-eses-Sub-study-003
gsk-205801-003-layperson-summary-of-results-dede-Sub-study-003

Trial Locations

Country Location
Canada, AB Edmonton, AB, Canada, T6G 1Z2
Canada, ON Brampton, ON, Canada, L6R 3J7
Canada, ON Toronto, ON, Canada, M5G 2M9
France Bordeaux, France, 33076
France Paris, France, 75248
France Paris, France, 75018
France VILLEJUIF CEDEX, France, 94805
Germany Grosshansdorf, Germany, 22927
Italy Meldola FC, Italy, 47014
Italy Milano, Italy, 20133
Italy Siena, Italy, 53100
Spain Barcelona, Spain, 08035
Spain Madrid, Spain, 28034
Spain Malaga, Spain, 29010
United States, TN Nashville, TN, United States, 37203